ORGANIGRAM GLOBAL INC

OGI stock represents shares of Organigram Holdings Inc., a Canadian cannabis company. The ticker trades on the NASDAQ exchange, giving U.S. investors exposure to the legal cannabis and cannabinoid sector. Organigram produces and distributes recreational and medical cannabis products, primarily serving the Canadian market while exploring international opportunities. As a small-cap stock, OGI can be more volatile than larger, diversified companies, so investors often review its filings and industry developments before making decisions.

Recent performance for OGI depends on shifting cannabis sector sentiment, company-specific news, and broader market conditions. For the latest price change and trend, refer to the live quote and performance chart displayed on this page. These figures update in real time, so checking the current data is more reliable than relying on any fixed number. Long-term investors often compare recent moves against the stock's historical range to judge momentum.

Because Organigram has reported losses in some periods, traditional earnings-based metrics like the P/E ratio may not be meaningful. Investors often review price-to-sales, price-to-book, and enterprise value multiples, along with cash position and share count. Comparing OGI's valuation to other cannabis producers can provide context. Current valuation metrics and market capitalization for OGI are shown on this page and should be checked for the most up-to-date figures.

OGI may be available for extended-hours trading through certain brokers that support pre-market and after-hours sessions. These windows are typically shorter, with lighter volume and wider spreads than the regular NASDAQ session. Liquidity can be thin, so price movements outside normal hours may not reflect the next day's opening price. Investors should confirm whether their brokerage offers this service and review the latest OGI quote on this page for current pricing.

Organigram operates in a heavily regulated industry, so changes in Canadian cannabis laws, licensing rules, or cross-border policies can affect results. The company faces competition from larger licensed producers, price pressure on cannabis products, and the challenge of reaching consistent profitability. As a smaller-cap stock, OGI may also experience sharp price swings and limited liquidity compared with blue-chip shares. Other risks include reliance on key markets, supply chain issues, and general equity market volatility.

Key metrics for Organigram include revenue growth, gross margin, adjusted EBITDA, net income or loss, operating cash flow, and cash on hand. These help assess whether the company is moving toward sustainable profitability. Share count and dilution are also relevant because capital raises can affect per-share value. Investors can find the latest quarterly and annual figures in OGI's financial statements and in the financial data section of this page, which should be reviewed for the most current numbers.